Tianshui Zhongxing Bio-technology Co.,Ltd.
Simbols: 002772.SZ
SHZ
7.08
CNYTirgus cena šodien
-764.5012
P/E koeficients
44.3411
PEG koeficients
2.78B
MRK Cap
- 0.00%
DIV ienesīgums
Tianshui Zhongxing Bio-technology Co.,Ltd. (002772-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1323.5 | 1695.7 | 1858.6 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 285 | 369.5 | 263.4 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 28.3 | 80.9 | 21.6 | |||||||||||||
balance-sheet.row.inventory | 0 | 1274.6 | 1255.5 | 1173.9 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 32.8 | 4.8 | 24.4 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 2659.2 | 3036.9 | 3078.5 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2946.8 | 3074 | 3005.4 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 334.4 | 342.4 | 350.6 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 334.4 | 342.4 | 350.6 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 123.7 | -285.2 | -170.9 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 268.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 9.7 | 401.1 | 19.3 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3414.6 | 3532.3 | 3472.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 6073.8 | 6569.1 | 6551.3 | |||||||||||||
balance-sheet.row.account-payables | 0 | 179.1 | 205.4 | 155.6 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 1009.7 | 980.4 | 422.6 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 1 | 1 | 0.7 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1074.5 | 1622.5 | 2330.7 | |||||||||||||
Deferred Revenue Non Current | 0 | 102.9 | 118.5 | 127.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 266.7 | 252.2 | 234.8 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1074.7 | 1741 | 2480.6 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.3 | 0.3 | 0.3 | |||||||||||||
balance-sheet.row.total-liab | 0 | 2535.3 | 3184.5 | 3300.2 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 393.2 | 407.5 | 407.4 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 958.9 | 931.5 | 819.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 60 | 26.1 | 27.3 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2020.3 | 2016.6 | 1994.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 3432.5 | 3381.6 | 3248.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 6073.8 | 6569.1 | 6551.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 3 | 3.1 | 2.5 | |||||||||||||
balance-sheet.row.total-equity | 0 | 3435.5 | 3384.7 | 3251.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 408.7 | 84.3 | 92.5 | |||||||||||||
balance-sheet.row.total-debt | 0 | 2084.4 | 2602.9 | 2753.3 | |||||||||||||
balance-sheet.row.net-debt | 0 | 1045.9 | 1276.7 | 1158.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 159.6 | 158.9 | 54.3 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 268.9 | 275.4 | 257.5 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -10.9 | -28 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 10.9 | 28 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11.7 | -77.9 | -788.6 | |||||||||||||
cash-flows.row.account-receivables | 0 | 20.7 | -35.7 | 2.5 | |||||||||||||
cash-flows.row.inventory | 0 | -26.3 | -85.4 | -912.1 | |||||||||||||
cash-flows.row.account-payables | 0 | -6.1 | 43.2 | 121 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 107.8 | 137.3 | 63.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -107 | -245.9 | -286.5 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 3 | 0.4 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -400 | -1310 | -510 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 450 | 1172.5 | 959.4 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0.7 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -57 | -380.4 | 164.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -544.4 | -1520.6 | -680.8 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -117.9 | -170.3 | -148.7 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -92.9 | 1323 | 1459.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -755.2 | -367.9 | 630.1 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -287.7 | -254.6 | 380.6 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1038.5 | 1326.2 | 1580.8 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1326.2 | 1580.8 | 1200.2 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 524.5 | 493.7 | -413.7 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -107 | -245.9 | -286.5 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 417.5 | 247.8 | -700.2 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1928.1 | 1970.3 | 1556.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1500.6 | 1468.8 | 1268.2 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 427.5 | 501.5 | 288 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | 0.6 | 33.7 | 4.5 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 247.2 | 231 | 187.4 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1747.7 | 1699.8 | 1455.6 | |||||||||||||
income-statement-row.row.interest-income | 0 | 31.6 | 31 | 53.6 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 83.6 | 90.5 | 80.9 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -17.6 | -148.7 | -67.3 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.6 | 33.7 | 4.5 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -17.6 | -148.7 | -67.3 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 83.6 | 90.5 | 80.9 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 268.9 | 275.4 | 257.5 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 180.4 | 307.6 | 121.6 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 162.8 | 158.9 | 54.3 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | 3.2 | 0 | 66.7 | |||||||||||||
income-statement-row.row.net-income | 0 | 159.6 | 158.4 | -12.4 |
Biežāk uzdotie jautājumi
Kas ir Tianshui Zhongxing Bio-technology Co.,Ltd. (002772.SZ) kopējie aktīvi?
Tianshui Zhongxing Bio-technology Co.,Ltd. (002772.SZ) kopējie aktīvi ir 6073765300.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.149.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.517.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.002.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.001.
Kāda ir Tianshui Zhongxing Bio-technology Co.,Ltd. (002772.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 159581340.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 2084417918.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 247154405.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.